Free Diagnostic Testing as a Pharmaceutical Kickback: Turning Test Results Into Sales Leads

Whistleblower Justice Network

A free diagnostic test can be a pharmaceutical kickback when a drugmaker supplies the testing to induce prescriptions paid by government health programs. The company pays for the test, receives the result and gives its sales team a reason to call the provider. QOL Medical, the company selling Sucraid, tracked whether positive breath tests turned into prescriptions for its drug. For laboratory, clinical and sales staff, that is the connection worth examining: a test offered to answer a patient’s medical question also supplied the next sales lead.

How Do Pharmaceutical Kickbacks Work?

Pharmaceutical kickbacks work by giving someone something of value to influence prescribing, purchasing or referrals for drugs paid for by federal healthcare programs. A free diagnostic service can supply that value. The benefit reaches the provider or patient through the testing, while the manufacturer seeks its return through prescriptions.

Free drug samples and free diagnostics reach that commercial objective at different points. A sample puts the drug in someone’s hands. A diagnostic program can reach the prescribing decision earlier, by supplying a result that the sales representative uses to promote treatment.

Free Diagnostic Test Results Sent to the Sales Team

In the pharmaceutical industry, free diagnostic test results sent to a sales team can become instructions about which providers to visit next. QOL’s program connected the laboratory result to a sales call and then measured whether that call produced a prescription.

According to the Justice Department’s account of QOL’s testing program, the company began distributing free Carbon-13 breath test kits to health care providers in 2018. It asked providers to give the kits to patients with common gastrointestinal symptoms. QOL paid a laboratory to analyze the tests and report the results to the providers. The laboratory also sent the results to QOL.

Between 2018 and 2022, QOL passed that information to its sales force with instructions to call providers whose patients had positive results. It tracked whether representatives converted positive tests into Sucraid prescriptions. The company could therefore follow the testing program beyond kit distribution and laboratory analysis to the drug sale it wanted.

A report about the patient’s test became a report about the representative’s next opportunity.

What the QOL Settlement Covered

QOL and its chief executive jointly agreed to a $47 million civil settlement, announced on November 15, 2024, resolving allegations that free breath testing induced Sucraid claims. The company and its executive accepted responsibility for certain facts about the program. From the federal share of that settlement, the Justice Department announced approximately $8 million for the whistleblowers.

The account also reaches management. The chief executive approved the distribution of the test kits and reviewed the national sales training. The testing program and its sales message reached the same decision-maker.

Claims resulting from a kickback can be false claims under the False Claims Act. In QOL, the government’s allegation concerned Sucraid claims induced through free testing. The manufacturer paid for the diagnostic service, and the government pursued the connection to the drug claims it generated.

A Positive Breath Test Became a Sales Pitch

QOL’s Carbon-13 breath test did not specifically diagnose CSID, the condition the company claimed it could identify or exclude. Approximately 30% of QOL’s tests were positive for low sucrase activity. That was the result QOL used to direct its sales calls.

The company’s suggested sales message went further. At a national sales training in 2019, QOL suggested that representatives tell providers a patient with a positive breath test would not improve without Sucraid. The laboratory reported low sucrase activity. The sales message turned that result into a reason to use Sucraid.

The whistleblowers’ amended complaint alleges what happened when doctors asked about reliability:

If doctors asked about the reliability of the Breath Test, Relators were instructed to “make something up” or “change the subject” rather than get drawn into an awkward conversation.

United States ex rel. John Does 1 through 4 v. QOL Medical LLC, et al., amended complaint, paragraph 89, whistleblower allegation

The complaint also alleges that the convenience and diagnostic imprecision of the free tests steered patients away from genetic testing or biopsies that would reveal most did not have CSID. Patients needed a diagnosis. In the whistleblowers’ account, the program steered them toward more prescriptions instead. The resulting drug claims were the cost the government pursued.

The same complaint alleges that QOL used drug distribution data to identify prescribers of IBS medications and target them for free breath tests. Its account therefore describes targeting before the kit reached the practice, as well as the government’s account of calls after a positive result. Existing prescribing helped select the audience, and the new test result supplied the follow-up.

Ultragenyx’s Genetic Tests and Marketing Data

Ultragenyx allegedly paid for genetic tests and separately paid for test-result information used to induce Crysvita prescriptions and referrals. Its $6 million settlement, announced on December 21, 2023, was smaller than QOL’s, but again concerned the use of diagnostic testing to sell a drug. The Justice Department’s Ultragenyx announcement identifies Medicare and Medicaid recoveries.

The separate payment for information makes this a useful comparison. Funding a test creates the result. Paying for access to information about that result gives the manufacturer another commercial tool. The allegation concerns how the company used both to induce drug business.

In QOL, the laboratory returned results that fed targeted calls. In Ultragenyx, the government alleged a separate payment for the information used to induce prescriptions and referrals. Both put the information coming out of the laboratory at the center of the sales story.

What Evidence Is Needed to Prove Fraud?

Evidence in a free-testing kickback case connects the funded test, the result, the sales activity and the government-paid drug claim. QOL’s laboratory arrangement, sales instructions and conversion tracking show how those connections can appear inside a business.

Laboratory staff may understand where the result went after analysis and who requested that it be sent. Clinical staff may know the difference between what the test measured and what the promotional materials promised. Sales representatives may recognize the provider lists, follow-up instructions and prescription expectations. Staff responsible for commercial reporting may understand how management counted a positive result as a converted prescription.

The sequence gives each person’s knowledge a place. The testing arrangement explains the benefit. The laboratory report supplies the result. The sales instructions connect that result to a provider. The prescription tracking shows the company’s commercial measure of success.

A False Claims Act Case Can Reward the Whistleblower

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

The QOL qui tam case came from whistleblowers who could describe instructions inside the sales operation. The movement of results from laboratory to company to representative may be routine to someone doing that work. It is also the connection that explains how the testing program served the prescription campaign.

When You Know Where the Test Results Went

If you have seen laboratory results become sales assignments, speak with our whistleblower experts about where the test results went. We help you turn what you know about the result feed and prescription tracking into a case that shows the commercial purpose behind the free test. We bring in whistleblower lawyers who know manufacturer kickbacks and work beside you throughout the case.

WHISTLEBLOWER JUSTICE NETWORK CAN HELP YOU
Make a difference.
Whistleblower Justice NetworkReport Fraud
100% CONFIDENTIALFREE CONSULTATION24 / 7 / 365